CoChat

Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials

Open access
Ussher, John R., Greenwell, Amanda A., Nguyen, My-Anh, Mulvihill, Erin E. · 2022 · Diabetes
Cited by 50

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

As the worldwide prevalence of diabetes and obesity continues to rise, so does the risk of debilitating cardiovascular complications. Given the significant association between diabetes and cardiovascular risk, the actions of glucose-lowering therapies within the cardiovascular system must be clearly defined. Incretin hormones, including GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide), are gut hormones secreted in response to nutrient intake that maintain glycemic control by regulating insulin and glucagon release. GLP-1 receptor agonists (GLP-1Ras) and dipeptidyl peptidase 4 inhibitors (DPP-4is) represent two drug classes used for the treatment of type 2 diabetes mellitus (T2DM) that improve glucose regulation through stimulating the actions of gut-derived incretin hormones or inhibiting their degradation, respectively. Despite both classes acting to potentiate the incretin response, the potential cardioprotective benefits afforded by GLP-1Ras have not been recapitulated in cardiovascular outcome trials (CVOTs) evaluating DPP-4is. This review provides insights through discussion of clinical and preclinical studies to illuminate the physiological mechanisms that may underlie and reconcile observations from GLP-1Ra and DPP-4i CVOTs. Furthermore, critical knowledge gaps and areas for further investigation will be emphasized to guide future studies and, ultimately, facilitate improved clinical management of cardiovascular disease in T2DM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dbi20-0049

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Research works printed but not linked: 44

  1. Gopal, 2020, The impact of antidiabetic therapies on diastolic dysfunction and diabetic cardiomyopathy, Front Physiol, 11, 603247, 10.3389/fphys.2020.603247 · DOI
  2. Sanada, 2021, Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: the earlier, the better, Sci Rep, 11, 1425, 10.1038/s41598-020-80894-x · DOI · Paper page
  3. Sudo, 2017, Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits, Atherosclerosis, 265, 283, 10.1016/j.atherosclerosis.2017.06.920 · DOI
  4. Koska, 2021, The effect of exenatide once weekly on carotid atherosclerosis in individuals with type 2 diabetes: an 18-month randomized placebo-controlled study, Diabetes Care, 44, 1385, 10.2337/dc20-2014 · DOI · Paper page
  5. Fonseca, 2014, Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials, J Diabetes Complications, 28, 399, 10.1016/j.jdiacomp.2014.01.009 · DOI · Paper page
  6. Li, 2014, Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients, Cardiovasc Diabetol, 13, 36, 10.1186/1475-2840-13-36 · DOI · Paper page
  7. Gaspari, 2011, A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model, Diab Vasc Dis Res, 8, 117, 10.1177/1479164111404257 · DOI · Paper page
  8. Moberly, 2012, Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow, Exp Biol Med (Maywood), 237, 334, 10.1258/ebm.2011.011288 · DOI
  9. Lønborg, 2012, Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia, Circ Cardiovasc Interv, 5, 288, 10.1161/CIRCINTERVENTIONS.112.968388 · DOI · Paper page
  10. Holman, 2017, Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes, N Engl J Med, 377, 1228, 10.1056/NEJMoa1612917 · DOI · Paper page
  11. Bao, 2011, Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency, PLoS One, 6, e23570, 10.1371/journal.pone.0023570 · DOI · Paper page
  12. Sassoon, 2017, Glucagon-like peptide 1 receptor activation augments cardiac output and improves cardiac efficiency in obese swine after myocardial infarction, Diabetes, 66, 2230, 10.2337/db16-1206 · DOI · Paper page
  13. Shiraki, 2019, GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy, Cardiovasc Diabetol, 18, 164, 10.1186/s12933-019-0966-2 · DOI
  14. Almutairi, 2021, The GLP-1 receptor agonist liraglutide increases myocardial glucose oxidation rates via indirect mechanisms and mitigates experimental diabetic cardiomyopathy, Can J Cardiol, 37, 140, 10.1016/j.cjca.2020.02.098 · DOI · Paper page
  15. Ding, 2019, Exenatide protects against cardiac dysfunction by attenuating oxidative stress in the diabetic mouse heart, Front Endocrinol (Lausanne), 10, 202, 10.3389/fendo.2019.00202 · DOI · Paper page
  16. Hussein, 2020, Comparative study of the effects of GLP1 analog and SGLT2 inhibitor against diabetic cardiomyopathy in type 2 diabetic rats: possible underlying mechanisms, Biomedicines, 8, 43, 10.3390/biomedicines8030043 · DOI
  17. Koyani, 2018, Saxagliptin but not sitagliptin inhibits CaMKII and PKC via DPP9 inhibition in cardiomyocytes, Front Physiol, 9, 1622, 10.3389/fphys.2018.01622 · DOI
  18. Mulvihill, 2014, Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors, Endocr Rev, 35, 992, 10.1210/er.2014-1035 · DOI · Paper page
  19. Yang, 2016, Increased plasma dipeptidyl peptidase-4 activities in patients with coronary artery disease, PLoS One, 11, e0163027, 10.1371/journal.pone.0163027 · DOI
  20. Zheng, 2015, Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of subclinical atherosclerosis in Chinese patients with newly diagnosed type 2 diabetes: a cross-sectional study, Atherosclerosis, 242, 580, 10.1016/j.atherosclerosis.2015.07.042 · DOI
  21. Barchetta, 2019, Greater circulating DPP4 activity is associated with impaired flow-mediated dilatation in adults with type 2 diabetes mellitus, Nutr Metab Cardiovasc Dis, 29, 1087, 10.1016/j.numecd.2019.07.010 · DOI
  22. Cho, 2019, Soluble dipeptidyl peptidase-4 levels are associated with decreased renal function in patients with type 2 diabetes mellitus, Diabetes Metab J, 43, 97, 10.4093/dmj.2018.0030 · DOI
  23. Nargis, 2018, Significance of circulatory DPP4 activity in metabolic diseases, IUBMB Life, 70, 112, 10.1002/iub.1709 · DOI · Paper page
  24. Lettau, 2020, Degranulation of human cytotoxic lymphocytes is a major source of proteolytically active soluble CD26/DPP4, Cell Mol Life Sci, 77, 751, 10.1007/s00018-019-03207-0 · DOI
  25. Ghorpade, 2018, Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance, Nature, 555, 673, 10.1038/nature26138 · DOI · Paper page
  26. Varin, 2019, Circulating levels of soluble dipeptidyl peptidase-4 are dissociated from inflammation and induced by enzymatic DPP4 inhibition, Cell Metab, 29, 320, 10.1016/j.cmet.2018.10.001 · DOI · Paper page
  27. Lee, 2019, Hepatocyte-specific HIF-1α ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation, Sci Adv, 5, eaaw4176, 10.1126/sciadv.aaw4176 · DOI
  28. Ohnuma, 2005, CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells, Mol Cell Biol, 25, 7743, 10.1128/MCB.25.17.7743-7757.2005 · DOI
  29. Baggio, 2020, Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans, Nat Commun, 11, 3766, 10.1038/s41467-020-17556-z · DOI
  30. Ikeda, 2013, Soluble CD26/dipeptidyl peptidase IV enhances the transcription of IL-6 and TNF-α in THP-1 cells and monocytes, PLoS One, 8, e66520, 10.1371/journal.pone.0066520 · doi:10.1371/journal.pone.0066520
  31. Lee, 2016, Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate, Metabolism, 65, 89, 10.1016/j.metabol.2015.10.002 · DOI
  32. Kubota, 2016, DPP-4 inhibition has beneficial effects on the heart after myocardial infarction, J Mol Cell Cardiol, 91, 72, 10.1016/j.yjmcc.2015.12.026 · DOI
  33. Sauvé, 2010, Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice, Diabetes, 59, 1063, 10.2337/db09-0955 · DOI · Paper page
  34. Batchu, 2018, The dipeptidyl peptidase 4 substrate CXCL12 has opposing cardiac effects in young mice and aged diabetic mice mediated by Ca2+ flux and phosphoinositide 3-kinase γ, Diabetes, 67, 2443, 10.2337/db18-0410 · DOI
  35. Mulvihill, 2016, Inhibition of dipeptidyl peptidase-4 impairs ventricular function and promotes cardiac fibrosis in high fat-fed diabetic mice, Diabetes, 65, 742, 10.2337/db15-1224 · DOI · Paper page
  36. Gross, 2016, Combined therapy with sitagliptin plus granulocyte-colony stimulating factor in patients with acute myocardial infarction-Long-term results of the SITAGRAMI trial, Int J Cardiol, 215, 441, 10.1016/j.ijcard.2016.04.134 · DOI
  37. Crowley, 2017, Metformin use may moderate the effect of DPP-4 inhibitors on cardiovascular outcomes, Diabetes Care, 40, 1787, 10.2337/dc17-1528 · DOI · Paper page
  38. Wang, 2017, Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients, Medicine (Baltimore), 96, e7638, 10.1097/MD.0000000000007638 · DOI
  39. Mulherin, 2011, Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell, Endocrinology, 152, 4610, 10.1210/en.2011-1485 · DOI · Paper page
  40. Dugani, 2021, Association of lipid, inflammatory, and metabolic biomarkers with age at onset for incident coronary heart disease in women, JAMA Cardiol, 6, 437, 10.1001/jamacardio.2020.7073 · DOI · Paper page
  41. Goodwill, 2014, Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism, Basic Res Cardiol, 109, 426, 10.1007/s00395-014-0426-9 · DOI
  42. Varin, 2020, Hematopoietic cell- versus enterocyte-derived dipeptidyl peptidase-4 differentially regulates triglyceride excursion in mice, JCI Insight, 5, e140418, 10.1172/jci.insight.140418 · DOI
  43. Grasset, 2017, A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism, Cell Metab, 26, 278, 10.1016/j.cmet.2017.06.003 · DOI
  44. Overgaard, 2021, Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes, Cell Rep Med, 2, 100387, 10.1016/j.xcrm.2021.100387 · DOI · Paper page

Cited by

See all 50

Metadata

Authors
Ussher, J. R., Greenwell, A. A., Nguyen, M.-A., & Mulvihill, E. E.
Venue
Diabetes
Published
2022-01-11
Volume
71
Issue
2
Pages
173-183
ISSN
0012-1797 (ISSN-L)
OpenAlex
W4205521731
Cited by
50
References
32
FWCI
6.63
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials. https://app.cochat.ai/papers/10.2337/dbi20-0049
The paper
Ussher, J. R., Greenwell, A. A., Nguyen, M.-A., & Mulvihill, E. E. (2022). Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials. Diabetes. https://doi.org/10.2337/dbi20-0049

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.